ARMATA PHARMACEUTICALS, INC. Other Nonoperating Expense
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Other Nonoperating Expense of $6.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. other nonoperating expense for the quarter ending 2026-06-30 was $6.63M, a 74.21% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. other nonoperating expense for the quarter ending 2026-03-31 was $5.56M, a 54.33% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. other nonoperating expense for the quarter ending 2025-12-31 was $4.83M, a 47.38% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. other nonoperating expense for the quarter ending 2025-09-30 was $4.35M, a 48.68% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. other nonoperating expense for fiscal 2025 was $16.59M, a 54.44% increase from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. other nonoperating expense for fiscal 2024 was $10.74M, a 309.06% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. other nonoperating expense for fiscal 2023 was $2.63M.
- ARMATA PHARMACEUTICALS, INC. other nonoperating expense for fiscal 2017 was $6.00K, a 98.92% decline from fiscal 2016.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.63M 10-Q · filed 2026-08-12 | $12.19M 10-Q · filed 2026-08-12 | $17.03M derived: sum of 3 quarters · filed 2026-08-12 | $21.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $5.56M 10-Q · filed 2026-05-13 | $10.39M derived: sum of 2 quarters · filed 2026-05-13 | $14.74M derived: sum of 3 quarters · filed 2026-05-13 | $18.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $4.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $9.18M derived: sum of 2 quarters · filed 2026-03-25 | $12.99M derived: sum of 3 quarters · filed 2026-08-12 | $16.59M 10-K · filed 2026-03-25 |
| 2025-09-30 | $4.35M 10-Q · filed 2025-11-12 | $8.15M derived: sum of 2 quarters · filed 2026-08-12 | $11.76M 10-Q · filed 2025-11-12 | $15.04M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $3.81M 10-Q · filed 2026-08-12 | $7.41M 10-Q · filed 2026-08-12 | $10.69M derived: sum of 3 quarters · filed 2026-08-12 | $13.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.60M 10-Q · filed 2026-05-13 | $6.88M derived: sum of 2 quarters · filed 2026-05-13 | $9.80M derived: sum of 3 quarters · filed 2026-05-13 | $12.52M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $3.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $6.20M derived: sum of 2 quarters · filed 2026-03-25 | $8.92M derived: sum of 3 quarters · filed 2026-03-25 | $10.74M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.92M 10-Q · filed 2025-11-12 | $5.64M derived: sum of 2 quarters · filed 2025-11-12 | $7.46M 10-Q · filed 2025-11-12 | $8.91M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.72M 10-Q · filed 2025-08-12 | $4.54M 10-Q · filed 2025-08-12 | $5.99M derived: sum of 3 quarters · filed 2025-08-12 | $7.16M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.82M 10-Q · filed 2025-05-14 | $3.27M derived: sum of 2 quarters · filed 2025-05-14 | $4.45M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $2.63M derived: sum of 2 quarters · filed 2025-03-21 | $2.63M 10-K · filed 2025-03-21 | |
| 2023-09-30 | $1.18M 10-Q · filed 2024-11-13 | $1.18M 10-Q · filed 2024-11-13 | ||
| 2017-12-31 | $6.00K 10-K · filed 2019-03-25 | |||
| 2017-03-31 | $1.00K 10-Q · filed 2018-05-15 | $328.00K derived: sum of 2 quarters · filed 2018-05-15 | $328.00K derived: sum of 3 quarters · filed 2018-05-15 | $555.00K derived: sum of 4 quarters · filed 2018-05-15 |
| 2016-12-31 | $327.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $327.00K derived: sum of 2 quarters · filed 2018-03-14 | $554.00K derived: sum of 3 quarters · filed 2018-03-14 | $554.00K 10-K · filed 2018-03-14 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $227.00K derived: sum of 2 quarters · filed 2017-11-14 | $227.00K 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $227.00K 10-Q · filed 2017-08-14 | $227.00K 10-Q · filed 2017-08-14 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27 | -$129.00K derived: sum of 2 quarters · filed 2017-03-27 | -$129.00K derived: sum of 3 quarters · filed 2017-03-27 | $302.00K 10-K · filed 2017-03-27 |
| 2015-09-30 | -$129.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$129.00K derived: sum of 2 quarters · filed 2016-11-10 | $302.00K 10-Q · filed 2016-11-10 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $431.00K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $431.00K 10-Q · filed 2016-05-12 | |||
| 2014-03-31 | $8.77M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |